Flow cytometric analysis showed that PD-1 antibody therapy potentiated an increase in the number of CD8+ T and NK cells in tumors of CB2-/- mice (Figures 7H–K), but not in WT (Figures 7D-G), indicating that the deletion of CB2 in the TME favors an enhanced responsiveness to PD-1 therapy and causes a reduction in tumor burden. The gene discussed is CD8A; the disease is neoplasm.